Servier, an independent international pharmaceutical group, has released the highlights of its 2024–2025 fiscal year, marked by sustained growth, major scientific advances, and continued progress toward the Group’s 2030 strategic ambition. These achievements further strengthen Servier’s impact in Canada and reaffirm our long‑term commitment to patients, healthcare professionals, and scientific partners across the country..

Key Highlights

• Strong momentum supporting the 2030 strategy: The Group delivered another year of solid growth, reinforcing the progress made toward its 2030 ambition. Consolidated revenue increased across all major therapeutic areas, supported by strong international performance — results that also strengthen Servier’s impact and sustained investment in Canada.
• Advances in oncology and CMVD: Significant R&D progress was achieved in oncology, including advancements in hard‑to‑treat cancers, further strengthening Servier’s leadership in this area. Innovation also continued in cardiometabolism and venous disease, where Servier remains a global reference and a key partner for Canadian healthcare professionals.
• Neuroscience gaining momentum: Neuroscience continued to expand as a strategic priority, with new developments reflecting the Group’s long‑term vision to address critical unmet patient needs — an area of increasing importance within the Canadian healthcare landscape.
• A strengthened pipeline focused on innovation: Servier’s R&D teams made meaningful progress across the pipeline, particularly in oncology and neuroscience, reaffirming the Group’s commitment to high‑value innovation and to bringing solutions that can benefit patients in Canada and around the world.